Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Status:
Terminated
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This study is for subjects diagnosed with recurrent or relapsed CLL/SLL. The purpose of this
study is to test the safety of the combination of the drugs lenalidomide and ibrutinib at
different dose levels, in combination with the drug rituximab. We want to find out what
effects, good and/or bad, they have on patients with CLL/SLL.
The hypothesis of the study is that it will be safe to give the three drugs in combination
and the information learned from this trial will be used to study the 3 drug combination is a
larger future trial.